0001356576-13-000026.txt : 20130905 0001356576-13-000026.hdr.sgml : 20130905 20130905161203 ACCESSION NUMBER: 0001356576-13-000026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20130905 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130905 DATE AS OF CHANGE: 20130905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 131080565 BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 supn-20130905x8k.htm 8-K d4551cf635db4ef

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2013

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of Incorporation)

 

0-50440

 

20-2590184

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

1550 East Gude Drive, Rockville MD

 

20850

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (301) 838-2500 

 

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

_________________________________________________________________________________________

 

 

Item 8.01            Other Events

On August 29, 2013, Supernus issued a press release announcing that the Company’s management will be presenting an overview of the Company at investor conferences on September 9, 2013 and September 12, 2013.   A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

On September 5, 2013, Supernus issued a press release announcing that Trokendi XR™ is now available to patients in the United States.  Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy.  The product has been shipped to major wholesalers in the market, and the Company’s sales force is promoting the product to physicians.  A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

 

Item 9.01            Financial Statements and Exhibits

            (d)            Exhibits

The following documents are furnished as Exhibits pursuant to Item 8.01 hereof:

Exhibit 99.1 – Press Release dated August 29, 2013 of the Company announcing that the Company’s management will be presenting at two investor conferences in September 2013.  

Exhibit 99.2 – Press Release dated September 5, 2013 of the Company announcing the commercial launch of Trokendi XR in the United States.

 

 

_________________________________________________________________________________________

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

                                                            SUPERNUS PHARMACEUTICALS, INC.

 

DATED:  September 5, 2013

By:  /s/            Gregory S. Patrick

 

Gregory S. Patrick

 

Vice-President and Chief Financial Officer

 

 

 

 

EXHIBIT INDEX

 

 

 

 

Number

Description

 

 

 

 

 

 

 

99.1

Press Release dated August 29, 2013.

Attached

 

99.2

Press Release dated September 5, 2013.

Attached

 

 

 

EX-99.1 2 supn-20130905ex99100b82c.htm EX-99.1 Press Release Investor Conferences Sept 2013 - FINAL

Supernus

EXHIBIT 99.1

FOR IMMEDIATE RELEASE                   

 

Supernus to Present at  Two Investor Conferences in September

 

Rockville, MD, August 29, 2013  -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will present an overview of the Company at the following investor conferences in September 2013:

 

Rodman & Renshaw:

Presentation Date:  Monday, September 9

Time:  11:40am ET

Place:  Millennium Broadway Hotel, NY

Stifel Nicolaus Weisel:

Presentation Date: Thursday, September 12

Time:  1:30pm ET

Place: Four Seasons Hotel, Boston, MA

 

About Supernus Pharmaceuticals, Inc.

 

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

 

 

CONTACTS:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

 

EX-99.2 3 supn-20130905ex992949d5d.htm EX-99.2 Press Release Trokendi Launch Sept 2013 FINAL

Supernus

EXHIBIT 99.2

FOR IMMEDIATE RELEASE                   

 

Supernus Launches Trokendi XR™ in the United States

 

Rockville, MD, September 5, 2013 --Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that Trokendi XR™ is now available to patients in the United States.  Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy.  The product has been shipped to major wholesalers in the market, and the Company’s sales force is promoting the product to physicians.

 

“We have built our sales force from the ground up, and this is our second product launch this year, representing a remarkable achievement for Supernus. Supernus is now a major player in epilepsy, offering two novel and differentiated products to patients. The Company continues its long standing heritage of excellence in execution against its corporate goals.  I would like to take this opportunity to thank all Supernus employees for their hard work and dedication that allowed us to launch Trokendi XR very shortly after receiving FDA approval,” said Jack Khattar,  President & CEO, of Supernus.   

 

About Trokendi XR™

Trokendi XR is a novel once-daily extended release formulation of topiramate. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

 

Forward Looking Statements

This press release contains forward-looking statements regarding the potential for Trokendi XR to treat epilepsy and the timing of the product's availability to physicians. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company's ability to commercialize the product successfully, whether physicians will prescribe and patients will use the product, once available, and competition in the market. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's Annual Report Form on 10-K that was filed with the United States Securities and Exchange Commission on March 15, 2013 and under the caption "Risk Factors" and the updates to these

 

risk factors in the Company's quarterly report on Form 10-Q that was filed with the Commission on August 14, 2013. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.

 

CONTACTS:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

GRAPHIC 4 supn-20130905ex99100b82cg1.gif GRAPHIC begin 644 supn-20130905ex99100b82cg1.gif M1TE&.#EA&@%!`(<``%9BF18J==[C:,G*WLG+WM[C:9&7O%9BFN3D[B@X?_+Q M]]?7YLG*W9&6O'1]JSA&B(.*LZRPS)"6NQ8I=?+P]D94D"@Y?ZVQS=+9:IZD MQ:^X;V5OHDU;=/C[O/SR?[[]B8W=IZCQ/GXY*^X;F9R#E+F?>#F<^GLFUIG7IB(N5 M<.7IA_W[]NONI/?VVN;KD>'F=.?KD?3TRC1#=?_\__[\]S1#=KN^UF5PH_;V MTO7UTG5]J^OMH_KYY')]@<.+G?6=ROMI.GK MF^/G??S[[:2L<%IH=/+SP*BMN^KMHXN6<>_PMZRQS=/9:[S!IX^9A,C,I_3T MT?[\]G>"A;S#;.?KDN7GP;B_E>CKF_?VV]_D:=[D:?_^_Q%&$-W[:K@0(*#"F%Y\0*`=6!; MK1F[9IWJMF[=ITUA,H4[MR]4D"]UK?0[$$&%H@<6%$0`02VO!'()2U8Y^6;- MMY(Q$[XZL^KDP0(5]!#+RT'G@A%V!=CU-R16S6XYVZT<.2'LK'ASWF[+$BYH MAQL<5WB8`:ABF8+CZE:NU^E>VIYII\1\.\F=4ECL2)&"!X\7+(*JT/^UR[&# M8UX$0C[@A;&V>]O19;]GWC7Y\N>4:6[F._6/F."8'E=3Q4`@X[F)`8+?=&6*E\\W$&XAR MEEBE='6FF%42:>1BZH`8$''>H60&5=2-9+;_THA#)9`V)'VA>@I?;UKE]:9S M%-()94S!%MNIKI;V8D@9!A:8"PLT!(5HJZ_:2-IY3M#BJ0%"6I#KL'R.IZ1- MU(E;+*9]G83NL0ZU@0:7I]KP`J*OIL7+!*Q*2R\-G"`4@5"&[D*"3H"1Z.F> M=B+[UUM/)@PLN"$A<6JS\E)K+[WYBC5!6$#14,A!`P"UVF,*N,;I;.MF"C&= M>8:;Y,IRD2&!"KP\X``"#ADRH*FXX+(*#43D4*]C&XNI**QAWNC$QP51H.]0 M%5`@G\D@+N!`#`8MD,%$'5!0$D<*###1$@.4W!(0']2E=0-`.(3`!;,M<$%% M'^`\+M5N,V``11\H_V80`@^(H)@"!EB0=H9MY($+@:>2(@,*+VRLQE`!I'#> MC==B?C$O5'!AT`QB!C6#WR*UP``!`VQM@`3M>8H``01,E!Y#(0`@%@XD*2!! M`O;N(@(#2>I"P`83$%64"!C51```O!PPD!FV4ZZ"V00!(H):G3%6Q--KV5V0 MZ0PPD$$)%0&?M]@-=.`0"144;[3-I/=2@19A'`#!S1$D<(16=6Q18*`%H@(O M-&"$'0Q%!VHYA!&(PJ:1L8F!D3K/"S!P!]11.!BH9X(R00U0D`-%[`($DTO!"L@$*QNQ2F2($@H(Q)"$ M@O0`1QL;V1`&!J2/3&$)0X`@%#IB&!P9*BPI%$@'8,"JU>3P>INKUQ`1LH`1 M`.4!(2`(`4:`HPJ<0"<1N"$.>[$`(.:++?D380!Z\0$6YBMI:LGD0*:0`5:Z MT'F+F<$O@R+,@5`@C`E@I$!ZXI@&",0`#A`>+WH!``GT(@+(',@="/1&4XU! M"1A0`@$'N!H0@,!5MC):F8`Y+1>DH2!32,"-5G/_J"'`+212=$PS9Z*`"-A. M-;D2E0R7(`D")*`?$[P0EC-2A#J<3M/"B"%Z[RS=O]$^!&/1H``!+ M`AP`@0>`E1=PTP4"-A"P:XT@`B!C(M8.0H(;\90@/L710(]`%"T>A'DI7$(/ M>F'4$SP@"[V`@&E[@00X_P*J0#?@A0N($(4:\(((`N0%!FQ%7*]:3',I*(`> MLK:>:Y$)A=XS"`&*MA;W,.!5;+$+!WDQ`J`:I#%"VL4#`CL0`XC,F@A1``,Q MI).8JN8Q:S&;`B!@@01XLS,.*!I0T%LB"+#*@R`)65$^.Y`UV;0C"SV2I]"8 M0@2P1P*\(,$'=I$_:?;B3\UZ(PAHD`LC-($(N]"!%=22BU89=UH6(Q,5QMJ1 M$X#7N61*0&$+0H"T$%@@1B4*3TE`IIMRUE5AP>Q`%,`(QY#W(/H,TTS1^*K5 M4J@A1HH43(QZKUVPUR!4CNNE<6+G))CEO&4&*8JB07`XAX@ZF ME*[+IH%&P.0)X.N3'<*%G37+5'O,10TROH9=K.`+8K'!$_A8W&Q?4+\8$$`D M&L($.FA)4('"``KZ?)Y1"F3177[(P`=\D*@'/B3J/0]Z)UT6BDB@(JN30`,D M0#[*-R#6.5<9YHKE[]GDF)F"%])`%:!/)@)@QKUZ""@,I*6[XZ(&;"C`V',! M@EW4(!?A?RR?6!,O9*P!'#IE`^?/2 M2'G9+37>Q<:\O9`*V(@71V\`_ZM&?1\J`X7"<`*'(`+3V`"N?`#NY`#N.`$.I(+(]9"]%(O(W,H&P-L MIB((O;`%<,0E@9)AN6`#2C`FO"!D.$8F/#48YD=I--9M)1$#-X)>W$(4YF,L MA<=`Z'<0[?<0I3:#TR<3:!0FUT<0EL9TPF+@-B6Z92;+-$$FAT*#7(6F6R:I\WAU)B<&J!)+UP`-]G8752 M,+VP)@"S:KVA$$:C,$_W(0.0B`^18RCD$!W`/!,X+:BG$KI`"?#",\T2!+Q@ M*G&&"RAP1[APAKR@`QT8.2>6(T)AG`D``!T*L'U7C=E'M-' M(>+&:-)H8R7A M82\7Z2I0ES0^YA%L2)&:M%V.<07&X@7.0HE;P@L\D`L\L`LND`LRB8`8(`-" M$01$67MZ-2T0%$\!R("\L(DMQX&`,I2X\%SV1F7%(TPTD7U`$94$P64'((@> MP4%$HA!A@#DDR1RZ\'DH>"PZ-10AX5QA&2:Y*)!JP8R%"$1D(A)LV9;E=(4@ M0"!\X`2Y@`'S,@>YX`(+M`MJ@`&_J8#\%$^_I0-*4'2V9RH_T(Y;PC.)&2A. M!2.A(X*Z2!HE.!!,]I%KR#$!-Q#G_R86(K@`JR*,4+%HH_F507&:E,-O6M&# M2ND0!8F"#6$`,6@0"F!"OC=3!X$%7I>8IZ()!(B.*RF7O)`"-O`L?*`61J`# M=9D+<&`%0<,!'(`"5,`#0K-,FJ@E5&4"03F&,/)US<("F*-!5"=2EZ(03SF' M!+$FVK<+-_42'R`M2:4IO$,49I05JI83A/@00C(!*`-P=*&,K4D5O`!#"(&( M0I*?"`&@;U0`=V3-M`EH5@4.8`"&A"F81H$.P!SF2,60@&B M!3)GO+`"6L)ZA_E4N(`*MN)W'>ELWN(0JH"06$:"(E%3N]`V-F%I9%)%#T$! M,P!#\>=`V?_%'-'H$(_*:N=1!`_!5BI:$#!PHPLQ!$+BGP:!!>5D*@4PJH"2 M`SE`(#S0IJ:B@"D`!SV#"*48*2()%";`>^>Q`K%8`-KW`BQYDHIICH!$AJ0L!*6)AJ`1Q!"!HIV5U0]C9D4"Q?7B#:M_RHV3I>[R@=071 MF1II$,Q3K1_11FH1 M-1.B"_D502)@A!0`9KN@I#.1=$D20>_QHW^C?8XQ`E[#$14+*R[_*A#,,P(; M11#TII9ZT08]0T[.TFL<<(FXX`@R8`0+*H`?^`)!@*^YX`.(L`,6R@%K$`5C MP`(ZX'QC@@+1:2!UIA8'2R"D&HL%R$`6=1`A5!0S,&K4-!9=@"]"@:RM@EEY MH0L*X%"NE%X_T2H)$`,$<`13$`(QD&32&IJ1HJQ.=R-RTFF.L1`FI"\5X+8Q MQ0L5``'%HWT#50(=:X2]``2.,7,EH;`&`B\$8@.[@`*`(@N60Y.X\`5LH!8I MX`1C4)<$PH\^,`8@$*OO20,I(`.B"D>QNQ!3P&`!(:=+E).VY>9>)[2\#P%AD0*1 M'G$"+U@4'=(;2_!'03$$`,"?25I_]7*]5P!#$G`H%=`Z?W=$$=824I!A4\J/ M!6(%N]`$/<,"I1@%<4=QL2N'-WE'>R0#@LJY)C<4SDIE^_88#K`W#A"Y"7!T-3$%QO1[H;L$!5&','8M(V,0 M(75_!&%BX;5^G<'"`',>0R"H]D=/ABI481$`/0`!CPS+"UL<`2T@J3AB`2%D+4"1:U!T,,Y4.*A8&@C@$1<` M;Q%U`#44;Z-,KCCP;O&6RA%%4Z9B8F M1)_I$$Q0N@.2L%Z7EPKJ+.FX"T+P`RY@QC=P`RM0`S^@`0MZQ[N@!"NP=CMP M*E)J*G%`$&&S-U```#C`Q>;3%@C0`"*``S?LI+H0`A`0`A*;FMIWF0N0!3$0 M41!@``1,,%OQ`08@`A%E`!&PL[J"'%__,QD(,-``4!;J4Q#R3,\AH3404$,W M3-%^:!`8*(9"*ZJ[20,O0`6GX@)^R0LRL`-!$&P:T`0:<`,H0`0O`!0@X"6\ M``*V5;JXP`13DC)J5(O-P2OB'$N&G"E*_3!#_2D000C<5RX#`:K+US,;&*H'8D5:39 M"T$!`0!@'"$E2M$0>^#>Z^K>$P/5&/`$(*!L(F,C-+`#/-"/4RJ=@D;@9XTK MK#F:>V*"AT,(7NM`"1D@E'&&?HCT04G"[XLC:M_6F M4]H$;O#23>`#N@U'MN54N2`&/+T1)`X5YG>SXK(FC>I?SL,MG2V##?_S+69] MU`NQ`!9FVKVPX/DVUP)1!6+0:ZNML+'(Y$_E+&;,Y/`2E,Z2\1,@#6"V!VF:^FW&J^YY5=U'*A`",P*;!Q$NLI+%S9"V#`KC_9ENSZIA+G MY&:KZ;5I*I^P%5(AU]"A"S`*Z-6(@I9F&C[W`18"`/KWQX2:0V<)`!&@%@/0 M6!(0!C?$"PW0`C@03&83FOR)-Z6:[UP`>6,63#5R@NP M'M`+`"T0`]!+$D"@`@"0`-+^QX0`AV0P$(>7[3TP`D.0R7TA,1,3Y'+J?V4< ME)1XDNR:"UM02*&]W"8R$!-6%(KKX-:*3+7_I#_\:U\?,`-")!`7D`!`0``T M,VO#G@`/P*D$<#V+E3I"\0`70`!H`5N]\`8JT`'('0#IH0LQ,`.OU`)%X#Q7 M``,ELR%(XE-N0@$DP#L=:6D'0#Z316D1KQ@4D`#>LO,?,``.KX9MV`M%`$,` M0*R)_A$1+BC4S!&A>L' M<)1^\^H"80:4%@"&"BG\Q0M#X#4X8U00B18"#^P=R0M`%U/`Q"T0*45*!7X#05H>A``)L+P(,`6Z<%1$E(9_R!9H%`A*98QX8Q![ MO!"#3<\` M9E-CZ#F:(<-?S#,01F5-9V3+O=\+5P"?`_%JX@YO2,$MSL]OTZB&O="&6;`+ MD4QC9F-4)=`0AU=D``#/)B,32)`EJ;TE4(WG('V[^UB=I&H'`)&DUT""!0GJ M,IA0H2Z$"AT^)-AB``$"`QA0G)B1P8`3$'OI8L`+@$()O`@0Y'6@X(5`%GA) M(!A`)4$"`4H0/,"+8(>7!!%DJ#""UX!>``(41&A@:$.")6$.!*"SUX!=3P>* M[+7!I,,+&Q+P,C!05\J!%Q+L$DD!*=.%'GLQV9)+;BY2"!70T( M&J6Y*ZP"!PE*G&C`BT&OG!\,QHZ04.G-@0<"("30$^5(K1D21DC0.7C8JZ(I M-#C[!FECCPW9%DSEM\#?O'8+Z-V+5^YWNX$+S&+B]GI;Q8X?LEVOGG+C`9F1 M*NV`$D>O%KP<#&2@-+'LFTHXVHYBJ+ZPEN#%MEZ4FLV!71Y0@*`%(N#E@95Z M*4$U@BK8!4`#>]EEI"QX*6(!@J988)?_IBJM(;(&6&*@!0AL[[&$JI!"KL#J M"NRO[[B;:[NY_BK#DQSE6[)))H_C)0&U#%**J%[_3IBQ1`40Z(&7#5IH[J#Z M7BPJ@`H+A.!!7HP#Q()=(E@`@:\2Z*(!`%2@X`&1.O@`@#1#".`!!!8`X*N! MZIM!@0@00``K!81*`((&-N@!")&V5,%+%7O!BH$AU*+`/R?=8L(.OK3+I8"] M!%!U/!]SH2,3#SQ0++[Y1DT(/NK:8^PTM**,@:DNW'S@@@5FX(6L&=`:P:R4 M2$"VQ#0O@`&MD0!`ZX$((H"!%PL@6,!-R3+@91<2>EE`J&0A0&@!/7?Q\,H* MDGT@A)P`:$'."2]P"8`%#-[O`0L`>."`,W%]SP\D MTNA+K[R,I"L12=)S:#U;KG?-]25 M26:E==:0:ST9HI&G*]ILLJ=3F66T5X:;XOC.CMKMDIT4&VQ:^^@C[+=W9ZW"24:\[+H3M]N]QT1>//*8JV,J[%D9TGORMA,[_&_%&4 GRAPHIC 5 supn-20130905ex992949d5dg1.gif GRAPHIC begin 644 supn-20130905ex992949d5dg1.gif M1TE&.#EA&@%!`(<``%9BF18J==[C:,G*WLG+WM[C:9&7O%9BFN3D[B@X?_+Q M]]?7YLG*W9&6O'1]JSA&B(.*LZRPS)"6NQ8I=?+P]D94D"@Y?ZVQS=+9:IZD MQ:^X;V5OHDU;=/C[O/SR?[[]B8W=IZCQ/GXY*^X;F9R#E+F?>#F<^GLFUIG7IB(N5 M<.7IA_W[]NONI/?VVN;KD>'F=.?KD?3TRC1#=?_\__[\]S1#=KN^UF5PH_;V MTO7UTG5]J^OMH_KYY')]@<.+G?6=ROMI.GK MF^/G??S[[:2L<%IH=/+SP*BMN^KMHXN6<>_PMZRQS=/9:[S!IX^9A,C,I_3T MT?[\]G>"A;S#;.?KDN7GP;B_E>CKF_?VV]_D:=[D:?_^_Q%&$-W[:K@0(*#"F%Y\0*`=6!; MK1F[9IWJMF[=ITUA,H4[MR]4D"]UK?0[$$&%H@<6%$0`02VO!'()2U8Y^6;- MMY(Q$[XZL^KDP0(5]!#+RT'G@A%V!=CU-R16S6XYVZT<.2'LK'ASWF[+$BYH MAQL<5WB8`:ABF8+CZE:NU^E>VIYII\1\.\F=4ECL2)&"!X\7+(*JT/^UR[&# M8UX$0C[@A;&V>]O19;]GWC7Y\N>4:6[F._6/F."8'E=3Q4`@X[F)`8+?=&6*E\\W$&XAR MEEBE='6FF%42:>1BZH`8$''>H60&5=2-9+;_THA#)9`V)'VA>@I?;UKE]:9S M%-()94S!%MNIKI;V8D@9!A:8"PLT!(5HJZ_:2-IY3M#BJ0%"6I#KL'R.IZ1- MU(E;+*9]G83NL0ZU@0:7I]KP`J*OIL7+!*Q*2R\-G"`4@5"&[D*"3H"1Z.F> M=B+[UUM/)@PLN"$A<6JS\E)K+[WYBC5!6$#14,A!`P"UVF,*N,;I;.MF"C&= M>8:;Y,IRD2&!"KP\X``"#ADRH*FXX+(*#43D4*]C&XNI**QAWNC$QP51H.]0 M%5`@G\D@+N!`#`8MD,%$'5!0$D<*###1$@.4W!(0']2E=0-`.(3`!;,M<$%% M'^`\+M5N,V``11\H_V80`@^(H)@"!EB0=H9MY($+@:>2(@,*+VRLQE`!I'#> MC==B?C$O5'!AT`QB!C6#WR*UP``!`VQM@`3M>8H``01,E!Y#(0`@%@XD*2!! M`O;N(@(#2>I"P`83$%64"!C51```O!PPD!FV4ZZ"V00!(H):G3%6Q--KV5V0 MZ0PPD$$)%0&?M]@-=.`0"144;[3-I/=2@19A'`#!S1$D<(16=6Q18*`%H@(O M-&"$'0Q%!VHYA!&(PJ:1L8F!D3K/"S!P!]11.!BH9X(R00U0D`-%[`($DTO!"L@$*QNQ2F2($@H(Q)"$ M@O0`1QL;V1`&!J2/3&$)0X`@%#IB&!P9*BPI%$@'8,"JU>3P>INKUQ`1LH`1 M`.4!(2`(`4:`HPJ<0"<1N"$.>[$`(.:++?D380!Z\0$6YBMI:LGD0*:0`5:Z MT'F+F<$O@R+,@5`@C`E@I$!ZXI@&",0`#A`>+WH!``GT(@+(',@="/1&4XU! M"1A0`@$'N!H0@,!5MC):F8`Y+1>DH2!32,"-5G/_J"'`+212=$PS9Z*`"-A. M-;D2E0R7(`D")*`?$[P0EC-2A#J<3M/"B"%Z[RS=O]$^!&/1H``!+ M`AP`@0>`E1=PTP4"-A"P:XT@`B!C(M8.0H(;\90@/L710(]`%"T>A'DI7$(/ M>F'4$SP@"[V`@&E[@00X_P*J0#?@A0N($(4:\(((`N0%!FQ%7*]:3',I*(`> MLK:>:Y$)A=XS"`&*MA;W,.!5;+$+!WDQ`J`:I#%"VL4#`CL0`XC,F@A1``,Q MI).8JN8Q:S&;`B!@@01XLS,.*!I0T%LB"+#*@R`)65$^.Y`UV;0C"SV2I]"8 M0@2P1P*\(,$'=I$_:?;B3\UZ(PAHD`LC-($(N]"!%=22BU89=UH6(Q,5QMJ1 M$X#7N61*0&$+0H"T$%@@1B4*3TE`IIMRUE5AP>Q`%,`(QY#W(/H,TTS1^*K5 M4J@A1HH43(QZKUVPUR!4CNNE<6+G))CEO&4&*8JB07`XAX@ZF ME*[+IH%&P.0)X.N3'<*%G37+5'O,10TROH9=K.`+8K'!$_A8W&Q?4+\8$$`D M&L($.FA)4('"``KZ?)Y1"F3177[(P`=\D*@'/B3J/0]Z)UT6BDB@(JN30`,D M0#[*-R#6.5<9YHKE[]GDF)F"%])`%:!/)@)@QKUZ""@,I*6[XZ(&;"C`V',! M@EW4(!?A?RR?6!,O9*P!'#IE`^?/2 M2'G9+37>Q<:\O9`*V(@71V\`_ZM&?1\J`X7"<`*'(`+3V`"N?`#NY`#N.`$.I(+(]9"]%(O(W,H&P-L MIB((O;`%<,0E@9)AN6`#2C`FO"!D.$8F/#48YD=I--9M)1$#-X)>W$(4YF,L MA<=`Z'<0[?<0I3:#TR<3:!0FUT<0EL9TPF+@-B6Z92;+-$$FAT*#7(6F6R:I\WAU)B<&J!)+UP`-]G8752 M,+VP)@"S:KVA$$:C,$_W(0.0B`^18RCD$!W`/!,X+:BG$KI`"?#",\T2!+Q@ M*G&&"RAP1[APAKR@`QT8.2>6(T)AG`D``!T*L'U7C=E'M-' M(>+&:-)H8R7A M82\7Z2I0ES0^YA%L2)&:M%V.<07&X@7.0HE;P@L\D`L\L`LND`LRB8`8(`-" M$01$67MZ-2T0%$\!R("\L(DMQX&`,I2X\%SV1F7%(TPTD7U`$94$P64'((@> MP4%$HA!A@#DDR1RZ\'DH>"PZ-10AX5QA&2:Y*)!JP8R%"$1D(A)LV9;E=(4@ M0"!\X`2Y@`'S,@>YX`(+M`MJ@`&_J8#\%$^_I0-*4'2V9RH_T(Y;PC.)&2A. M!2.A(X*Z2!HE.!!,]I%KR#$!-Q#G_R86(K@`JR*,4+%HH_F507&:E,-O6M&# M2ND0!8F"#6$`,6@0"F!"OC=3!X$%7I>8IZ()!(B.*RF7O)`"-O`L?*`61J`# M=9D+<&`%0<,!'(`"5,`#0K-,FJ@E5&4"03F&,/)US<("F*-!5"=2EZ(03SF' M!+$FVK<+-_42'R`M2:4IO$,49I05JI83A/@00C(!*`-P=*&,K4D5O`!#"(&( M0I*?"`&@;U0`=V3-M`EH5@4.8`"&A"F81H$.P!SF2,60@&B M!3)GO+`"6L)ZA_E4N(`*MN)W'>ELWN(0JH"06$:"(E%3N]`V-F%I9%)%#T$! M,P!#\>=`V?_%'-'H$(_*:N=1!`_!5BI:$#!PHPLQ!$+BGP:!!>5D*@4PJH"2 M`SE`(#S0IJ:B@"D`!SV#"*48*2()%";`>^>Q`K%8`-KW`BQYDHIICH!$AJ0L!*6)AJ`1Q!"!HIV5U0]C9D4"Q?7B#:M_RHV3I>[R@=071 MF1II$,Q3K1_11FH1 M-1.B"_D502)@A!0`9KN@I#.1=$D20>_QHW^C?8XQ`E[#$14+*R[_*A#,,P(; M11#TII9ZT08]0T[.TFL<<(FXX`@R8`0+*H`?^`)!@*^YX`.(L`,6R@%K$`5C MP`(ZX'QC@@+1:2!UIA8'2R"D&HL%R$`6=1`A5!0S,&K4-!9=@"]"@:RM@EEY MH0L*X%"NE%X_T2H)$`,$<`13$`(QD&32&IJ1HJQ.=R-RTFF.L1`FI"\5X+8Q MQ0L5``'%HWT#50(=:X2]``2.,7,EH;`&`B\$8@.[@`*`(@N60Y.X\`5LH!8I MX`1C4)<$PH\^,`8@$*OO20,I(`.B"D>QNQ!3P&`!(:=+E).VY>9>)[2\#P%AD0*1 M'G$"+U@4'=(;2_!'03$$`,"?25I_]7*]5P!#$G`H%=`Z?W=$$=824I!A4\J/ M!6(%N]`$/<,"I1@%<4=QL2N'-WE'>R0#@LJY)C<4SDIE^_88#K`W#A"Y"7!T-3$%QO1[H;L$!5&','8M(V,0 M(75_!&%BX;5^G<'"`',>0R"H]D=/ABI481$`/0`!CPS+"UL<`2T@J3AB`2%D+4"1:U!T,,Y4.*A8&@C@$1<` M;Q%U`#44;Z-,KCCP;O&6RA%%4Z9B8F M1)_I$$Q0N@.2L%Z7EPKJ+.FX"T+P`RY@QC=P`RM0`S^@`0MZQ[N@!"NP=CMP M*E)J*G%`$&&S-U```#C`Q>;3%@C0`"*``S?LI+H0`A`0`A*;FMIWF0N0!3$0 M41!@``1,,%OQ`08@`A%E`!&PL[J"'%__,QD(,-``4!;J4Q#R3,\AH3404$,W M3-%^:!`8*(9"*ZJ[20,O0`6GX@)^R0LRL`-!$&P:T`0:<`,H0`0O`!0@X"6\ M``*V5;JXP`13DC)J5(O-P2OB'$N&G"E*_3!#_2D000C<5RX#`:K+US,;&*H'8D5:39 M"T$!`0!@'"$E2M$0>^#>Z^K>$P/5&/`$(*!L(F,C-+`#/-"/4RJ=@D;@9XTK MK#F:>V*"AT,(7NM`"1D@E'&&?HCT04G"[XLC:M_6F M4]H$;O#23>`#N@U'MN54N2`&/+T1)`X5YG>SXK(FC>I?SL,MG2V##?_S+69] MU`NQ`!9FVKVPX/DVUP)1!6+0:ZNML+'(Y$_E+&;,Y/`2E,Z2\1,@#6"V!VF:^FW&J^YY5=U'*A`",P*;!Q$NLI+%S9"V#`KC_9ENSZIA+G MY&:KZ;5I*I^P%5(AU]"A"S`*Z-6(@I9F&C[W`18"`/KWQX2:0V<)`!&@%@/0 M6!(0!C?$"PW0`C@03&83FOR)-Z6:[UP`>6,63#5R@NP M'M`+`"T0`]!+$D"@`@"0`-+^QX0`AV0P$(>7[3TP`D.0R7TA,1,3Y'+J?V4< ME)1XDNR:"UM02*&]W"8R$!-6%(KKX-:*3+7_I#_\:U\?,`-")!`7D`!`0``T M,VO#G@`/P*D$<#V+E3I"\0`70`!H`5N]\`8JT`'('0#IH0LQ,`.OU`)%X#Q7 M``,ELR%(XE-N0@$DP#L=:6D'0#Z316D1KQ@4D`#>LO,?,``.KX9MV`M%`$,` M0*R)_A$1+BC4S!&A>L' M<)1^\^H"80:4%@"&"BG\Q0M#X#4X8U00B18"#^P=R0M`%U/`Q"T0*45*!7X#05H>A``)L+P(,`6Z<%1$E(9_R!9H%`A*98QX8Q![ MO!"#3<\` M9E-CZ#F:(<-?S#,01F5-9V3+O=\+5P"?`_%JX@YO2,$MSL]OTZB&O="&6;`+ MD4QC9F-4)=`0AU=D``#/)B,32)`EJ;TE4(WG('V[^UB=I&H'`)&DUT""!0GJ M,IA0H2Z$"AT^)-AB``$"`QA0G)B1P8`3$'OI8L`+@$()O`@0Y'6@X(5`%GA) M(!A`)4$"`4H0/,"+8(>7!!%DJ#""UX!>``(41&A@:$.")6$.!*"SUX!=3P>* M[+7!I,,+&Q+P,C!05\J!%Q+L$DD!*=.%'GLQV9)+;BY2"!70T( M&J6Y*ZP"!PE*G&C`BT&OG!\,QHZ04.G-@0<"("30$^5(K1D21DC0.7C8JZ(I M-#C[!FECCPW9%DSEM\#?O'8+Z-V+5^YWNX$+S&+B]GI;Q8X?LEVOGG+C`9F1 M*NV`$D>O%KP<#&2@-+'LFTHXVHYBJ+ZPEN#%MEZ4FLV!71Y0@*`%(N#E@95Z M*4$U@BK8!4`#>]EEI"QX*6(!@J988)?_IBJM(;(&6&*@!0AL[[&$JI!"KL#J M"NRO[[B;:[NY_BK#DQSE6[)))H_C)0&U#%**J%[_3IBQ1`40Z(&7#5IH[J#Z M7BPJ@`H+A.!!7HP#Q()=(E@`@:\2Z*(!`%2@X`&1.O@`@#1#".`!!!8`X*N! MZIM!@0@00``K!81*`((&-N@!")&V5,%+%7O!BH$AU*+`/R?=8L(.OK3+I8"] M!%!U/!]SH2,3#SQ0++[Y1DT(/NK:8^PTM**,@:DNW'S@@@5FX(6L&=`:P:R4 M2$"VQ#0O@`&MD0!`ZX$((H"!%PL@6,!-R3+@91<2>EE`J&0A0&@!/7?Q\,H* MDGT@A)P`:$'."2]P"8`%#-[O`0L`>."`,W%]SP\D MTNA+K[R,I"L12=)S:#U;KG?-]25 M26:E==:0:ST9HI&G*]ILLJ=3F66T5X:;XOC.CMKMDIT4&VQ:^^@C[+=W9ZW"24:\[+H3M]N]QT1>//*8JV,J[%D9TGORMA,[_&_%&4